Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 1/20 | 0.56 |
| ▸ | CA4 | P22748 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2277677 | 0.91 | CA1 (0.58) | ACP3CA4ALDH1A1TDP1L3MBTL1 | |
| SCHEMBL28806943 | 0.90 | ALDH1A1 (0.51) | ACP3CA4LTA4HALDH1A1TDP1 | |
| SCHEMBL5941221 | 0.82 | PBRM1 (0.62) | ACP3CA4LTA4HALDH1A1TDP1 | |
| SCHEMBL14205685 | 0.82 | SLC2A1 (0.61) | ACP3CA4LTA4HALDH1A1TDP1 | |
| SCHEMBL13295535 | 0.82 | SLC2A1 (0.61) | ACP3CA4LTA4HALDH1A1TDP1 | |
| SCHEMBL40557 | 0.82 | SLC2A1 (0.61) | ACP3CA4LTA4HALDH1A1TDP1 | |
| SCHEMBL8429413 | 0.82 | PBRM1 (0.62) | ACP3CA4LTA4HALDH1A1TDP1 | |
| SCHEMBL13295540 | 0.82 | SLC2A1 (0.61) | ACP3CA4LTA4HALDH1A1TDP1 | |
| SCHEMBL13295537 | 0.82 | SLC2A1 (0.61) | ACP3CA4LTA4HALDH1A1TDP1 | |
| SCHEMBL34971 | 0.82 | SLC2A1 (0.61) | ACP3CA4LTA4HALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160031962-A1 | SOLID PHASE PEPTIDE SYNTHESIS OF INSULIN USING SIDE CHAIN ACHORED LYSINE | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2016-02-04 | — | — | US | claimed |
| EP-2838915-A1 | SOLID PHASE PEPTIDE SYNTHESIS OF INSULIN USING SIDE CHAIN ANCHORED LYSINE | Barlos, Kleomenis K. (GR) | 2015-02-25 | — | — | EP | claimed |
| WO-2013156977-A1 | SOLID PHASE PEPTIDE SYNTHESIS OF INSULIN USING SIDE CHAIN ANCHORED LYSINE | BARLOS KLEOMENIS K (GR) | 2013-10-24 | — | — | WO | claimed |
| CN-122059950-A | Compounds with proteasome agonistic activity, preparation method and application thereof | 浙大城市学院 | 2026-05-19 | — | — | CN | disclosed |
| US-12492225-B2 | Melanocyte-regulating peptides | IDP DISCOVERY PHARMA, S.L. (ES) | 2025-12-09 | — | — | US | disclosed |
| EP-4532513-A1 | CYCLIC PEPTIDES WITH ANTIBACTERIAL ACTIVITY AGAINST MULTIDRUG RESISTANT (MDR) PATHOGENS | Fundación Privada Instituto De Salud Global Barcelona (ES) | 2025-04-09 | — | — | EP | disclosed |
| CN-119451974-A | Cyclic peptides having antibacterial activity against Multiple Drug Resistant (MDR) pathogens | 巴塞罗那全球健康研究所私人基金会 | 2025-02-14 | — | — | CN | disclosed |
| US-20240328014-A1 | AMMONIA PRODUCTION METHOD AND AMMONIA PRODUCTION APPARATUS | THE UNIVERSITY OF TOKYO (JP) | 2024-10-03 | — | — | US | disclosed |
| WO-2024185801-A1 | AMMONIA PRODUCTION CATALYST AND METHOD FOR PRODUCING AMMONIA USING SAID CATALYST | 国立大学法人 東京大学 | 2024-09-12 | — | — | WO | disclosed |
| US-20240294573-A1 | CONSTRAINED PEPTIDES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-09-05 | — | — | US | disclosed |
| US-20240083943-A1 | VEGF-REGULATING PEPTIDES | IDP DISCOVERY PHARMA, S.L. (ES) | 2024-03-14 | — | — | US | disclosed |
| WO-2006084338-A1 | NOVEL TUBULIN POLYMERISATION INHIBITORS | BIONOMICS LIMITED (AU) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006002470-A1 | CHIRAL LIGANDS FOR ASYMMETRIC CATALYSIS | MONASH UNIVERSITY (AU) | 2006-01-12 | — | — | WO | disclosed |
| WO-2005070911-A1 | TRANSACETALISATION PROCESS | MONASH UNIVERSITY (AU) | 2005-08-04 | — | — | WO | disclosed |
| EP-0931062-B1 | CONJUGATES AND SPECIFIC IMMUNOASSAYS FOR THE METHADONE METABOLITE 2-ETHYLIDINE-1,5-DIMETHYL-3,3-DIPHENYLPYRROLIDINE | MICROGENICS CORP (US) | 2004-11-17 | — | — | EP | disclosed |
| US-6140137-A | METABOLITE LINKED TO POLYPEPTIDE FOR ANALYSIS AND ANTIBODY PRODUCTION; MONITORING COMPLIANCE WITH METHADONE TREATMENT | MICROGENICS CORPORATION (US) | 2000-10-31 | — | — | US | disclosed |
| EP-0931062-A1 | CONJUGATES AND SPECIFIC IMMUNOASSAYS FOR THE METHADONE METABOLITE 2-ETHYLIDINE-1,5-DIMETHYL-3,3-DIPHENYLPYRROLIDINE | MICROGENICS CORPORATION (US) | 1999-07-28 | — | — | EP | disclosed |
| WO-1998054133-A1 | CONJUGATES AND SPECIFIC IMMUNOASSAYS FOR THE METHADONE METABOLITE 2-ETHYLIDINE-1,5-DIMETHYL-3,3-DIPHENYLPYRROLIDINE | MICROGENICS CORPORATION (US) | 1998-12-03 | — | — | WO | disclosed |
| US-4792554-A | Pyridine compounds, pharaceutical compositions, their use in allergy therapy | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-12-20 | — | — | US | disclosed |
| EP-0224159-A1 | Pyridine compounds, substituted by basic groups, process for their preparation, medicaments containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12492225-B2 | Melanocyte-regulating peptides | MC1R, MITF, MCHR1 | ACP3 1556/4885CA4 4316/4885LTA4H 3142/4885 |
| US-20160031962-A1 | SOLID PHASE PEPTIDE SYNTHESIS OF INSULIN USING SIDE CHAIN ACHORED LYSINE | IAPP, INSRR, IGFBP6 | ACP3 2175/4885CA4 4265/4885LTA4H 4024/4885 |
| US-20240294573-A1 | CONSTRAINED PEPTIDES | IAPP, NGLY1, VIP | ACP3 356/4885CA4 1486/4885LTA4H 4331/4885 |
| US-20240083943-A1 | VEGF-REGULATING PEPTIDES | VEGFA, FLT4, FLT1 | ACP3 2301/4885CA4 405/4885LTA4H 4132/4885 |
| US-20240328014-A1 | AMMONIA PRODUCTION METHOD AND AMMONIA PRODUCTION APPARATUS | ASNS, ASS1, CPS1 | ACP3 2160/4885CA4 197/4885LTA4H 3854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.